Rapport d’analyse de la taille, de la part et des tendances du marché mondial des tests d’infections virales transmises par les arthropodes – Aperçu et prévisions de l’industrie jusqu’en 2031

Analyse du marché des tests d'infections virales transmises par les arthropodes

L'incidence mondiale de ces infections augmentant en raison de facteurs tels que le changement climatique, l'urbanisation et les voyages internationaux, la demande de solutions de test précises et rapides a augmenté. Le marché propose divers outils de diagnostic , notamment des tests moléculaires, des immuno-essais et des méthodes de culture. Les avancées récentes incluent le développement de tests moléculaires plus sensibles et portables. En outre, les collaborations entre les agences de santé publique et les sociétés de diagnostic visent à améliorer les capacités de réponse mondiale, favorisant ainsi la croissance du marché.

Taille du marché des tests d'infections virales transmises par les arthropodes

Français La taille du marché mondial des tests d’infections virales transmises par les arthropodes était évaluée à 1,14 milliard USD en 2023 et devrait atteindre 1,77 milliard USD d’ici 2031, avec un TCAC de 5,65 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l’épidémiologie des patients, l’analyse du pipeline, l’analyse des prix et le cadre réglementaire.

Tendances du marché des tests d'infections virales transmises par les arthropodes

« Innovations dans les technologies de diagnostic »

Les innovations dans les technologies de diagnostic, telles que les tests moléculaires et les immuno-essais au point d’intervention, transforment le marché en offrant une détection plus rapide et plus précise de ces infections. L’une des principales tendances est l’évolution vers des diagnostics rapides et portables, permettant aux prestataires de soins de santé de diagnostiquer rapidement les patients dans les zones reculées ou sujettes aux épidémies. Ces avancées améliorent la détection précoce et la gestion des infections virales, réduisant ainsi la propagation des maladies. Alors que les préoccupations mondiales en matière de santé publique se multiplient, la demande de solutions de test avancées et conviviales continue d’augmenter, ce qui en fait un domaine d’intérêt essentiel dans le secteur du diagnostic des soins de santé.

Portée du rapport et segmentation du marché des tests d'infections virales transmises par les arthropodes

Arthropod-Borne Viral Infections Testing Market Definition

Arthropod-Borne Viral Infections Testing refers to the diagnostic processes used to detect viruses transmitted by arthropods, such as mosquitoes, ticks, and fleas. These viruses, including dengue, Zika, chikungunya, and West Nile, cause diseases that can lead to severe health complications. Testing methods include molecular tests, immunoassays, and culture-based approaches, which help in the timely identification and management of these infections to prevent outbreaks and ensure appropriate treatment.

Arthropod-Borne Viral Infections Testing Market Dynamics

Drivers

• Rising Prevalence of Arthropod-Borne Diseases

The increasing incidence of arthropod-borne diseases such as dengue, Zika, chikungunya, and West Nile virus significantly drives the demand for advanced testing solutions. These viral infections, transmitted primarily through mosquitoes, have seen a notable rise in global cases due to factors such as climate change, urbanization, and increased travel. For instance, dengue cases have surged dramatically in tropical and subtropical regions, prompting urgent healthcare responses. Consequently, there is a pressing need for efficient and reliable diagnostic methods to facilitate early detection and management of these diseases, ultimately enhancing patient outcomes and public health initiatives. This trend underscores the critical need for innovative testing solutions in the market.

• Advancements in Molecular Diagnostic Technologies

Advancements in molecular diagnostic technologies, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), are pivotal in driving growth in the arthropod-borne viral infections testing market. These technologies allow for rapid and precise detection of viral pathogens, significantly enhancing diagnostic accuracy. PCR techniques can identify specific genetic material of viruses within hours, while NGS provides comprehensive genomic data, facilitating the understanding of viral mutations and epidemiology. As healthcare providers increasingly adopt these innovative testing solutions, they can respond more effectively to outbreaks and manage patient care, ultimately propelling the demand for molecular diagnostics in this critical sector of infectious disease testing.

Opportunities

• Telemedicine and Remote Testing Solutions

The rise of telemedicine and remote patient monitoring presents a significant opportunity for the arthropod-borne viral infections testing market, particularly through the development and distribution of at-home testing kits. These kits allow individuals in underserved regions to access diagnostic solutions conveniently, eliminating the barriers posed by distance and healthcare accessibility. As telehealth continues to grow, patients can conduct tests in the comfort of their homes and receive results quickly, facilitating timely medical intervention. This shift enhances patient engagement and reduces the burden on healthcare facilities, driving demand for innovative testing products tailored for remote use in the management of viral infections.

• Vaccine Development and Monitoring

The development of new vaccines for arthropod-borne diseases presents a significant market opportunity for specialized diagnostic solutions focused on efficacy and safety testing. As public health initiatives strive to combat viral infections such as dengue and Zika, the demand for comprehensive testing methods becomes essential to ensure vaccine performance and patient safety. Diagnostic tools that can accurately assess immune responses and identify adverse effects will be crucial in evaluating vaccine candidates during clinical trials and post-marketing surveillance. This need for rigorous testing supports vaccine development and fosters innovation in the diagnostics sector, driving growth and investment in cutting-edge testing technologies.

Restraints/Challenges

• High Cost of Molecular Diagnostic Technologies

The high costs associated with the development and implementation of advanced molecular diagnostic technologies, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), pose a significant challenge in the arthropod-borne viral infections testing market. These sophisticated technologies require substantial investment in equipment, reagents, and training, making them less accessible for smaller laboratories and healthcare providers, especially in low-resource settings. This financial barrier can lead to disparities in diagnostic capabilities, limiting timely and accurate testing in regions most affected by arthropod-borne diseases. Consequently, this challenge hampers effective disease management and control efforts, highlighting the need for more affordable and accessible testing solutions.

• Inconsistent Disease Surveillance

Variability in disease surveillance systems poses a significant restraint on the arthropod-borne viral infections testing market, as it can lead to incomplete and inconsistent data regarding infection prevalence. In many regions, particularly in low-resource settings, surveillance efforts may be underfunded or poorly organized, resulting in gaps in information about disease outbreaks and transmission patterns. This lack of reliable data can hinder effective public health responses, as decision-makers rely on accurate statistics to allocate resources and implement control measures. Consequently, the uncertainty in disease prevalence diminishes the perceived need for testing, negatively impacting market demand and stifling advancements in diagnostic capabilities.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Arthropod-Borne Viral Infections Testing Market Scope

The market is segmented on the basis of test type and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Molecular Tests
• Cultural Tests
• Immunoassays
• Others

End User

• Hospitals
• Research Centers
• Diagnostic Centers

Arthropod-Borne Viral Infections Testing Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, test type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the arthropod-borne viral infections testing market, driven by the swift advancement of diagnostic technologies in the region. The integration of innovative solutions, such as PCR and next-generation sequencing, enhances testing accuracy and efficiency. Furthermore, robust healthcare infrastructure and substantial investment in research contribute to the region's leadership in this market.

The Asia-Pacific region is projected to experience substantial growth in the arthropod-borne viral infections testing market from 2024 to 2031, primarily due to its large population at risk for infections. The high prevalence of arboviruses in this area further exacerbates the demand for effective diagnostic solutions. Additionally, increasing public health awareness and improved healthcare infrastructure are likely to drive this market expansion in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Arthropod-Borne Viral Infections Testing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Arthropod-Borne Viral Infections Testing Market Leaders Operating in the Market Are:

• Thermo Fisher Scientific, Inc. (U.S.)
• BioMérieux (France)
• Hologic, Inc. (U.S.)
• EUROIMMUN Medizinische Labordiagnostika AG (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• InBios International Inc. (U.S.)
• Quest Diagnostics Incorporated (États-Unis)
• CERTEST BIOTEC (Espagne)
• Réponse Biomédicale (Canada)
• Chembio Diagnostics, Inc. (États-Unis)
• Abbott (États-Unis)

Derniers développements sur le marché des tests d'infections virales transmises par les arthropodes

• En mai 2024, le Global Health Innovative Technology (GHIT) Fund a annoncé un investissement d'environ 1,64 milliard JPY (10,8 millions USD) visant à faire avancer quatre projets axés sur le développement de nouveaux traitements contre le paludisme et les maladies tropicales négligées. Cette initiative de financement souligne l'engagement de l'organisation à relever les défis sanitaires cruciaux dans les régions mal desservies. En soutenant le développement de médicaments innovants, le GHIT vise à améliorer les options thérapeutiques et les résultats en matière de santé pour les populations touchées dans le monde entier.
• En mai 2023, Astellas Pharma Inc. a annoncé son engagement envers le Fonds mondial pour les technologies innovantes en santé, qui vise à soutenir le développement de médicaments, d’outils de diagnostic et de vaccins destinés à lutter contre diverses maladies infectieuses. Cette contribution se concentre particulièrement sur les maladies tropicales méconnues qui manquent souvent de financement et de ressources suffisants. En investissant dans cette initiative, Astellas Pharma cherche à améliorer les résultats en matière de santé mondiale et à combler les lacunes critiques dans la gestion des maladies infectieuses
• En juillet 2022, Mylab Discovery Solutions a présenté son kit de test de maladies innovant, le « PathoDetect Extended Monsoon Fever Panel », qui a fait preuve d'une sensibilité et d'une spécificité impressionnantes. Ce panel avancé différencie efficacement plusieurs maladies infectieuses, notamment le paludisme, le chikungunya, la dengue, le Zika, la leptospirose, les espèces bactériennes de salmonellose et le parasite de la leishmaniose. Grâce à sa capacité à identifier avec précision plusieurs agents pathogènes, ce kit de test améliore les capacités de diagnostic pendant la saison de la mousson, répondant ainsi aux défis sanitaires critiques dans les régions touchées
• En novembre 2021, Achico, une entreprise suisse spécialisée dans les technologies de la santé, a annoncé le développement de kits de diagnostic spécifiquement destinés à la dengue. Ces kits de test innovants s'appuient sur la plateforme technologique d'aptamères ADN de l'entreprise, qui s'est avérée efficace pour diagnostiquer la COVID-19. En appliquant cette technologie avancée au diagnostic de la dengue, Achico vise à améliorer la précision et l'efficacité des tests de dépistage de cette importante maladie infectieuse
• En novembre 2021, l'entreprise suisse de technologie médicale Achico a dévoilé son projet de développement de kits de diagnostic pour la dengue. Ces kits de test innovants utiliseront la plateforme technologique d'aptamères ADN de l'entreprise, qui a déjà démontré son efficacité dans le diagnostic de la COVID-19. Cette avancée vise à améliorer les capacités de diagnostic de la dengue, répondant au besoin croissant de solutions de test fiables

SKU-63602